Breakthrough Therapies for Idiopathic Pulmonary Fibrosis

submitted by: mcgheek

Timothy P.M. Whelan, M.D., Medical Director of the Lung Transplant Program at the Medical University of South Carolina, discusses promising clinical trial results of new agents (pirfenidone, nintedanib) for the treatment of idiopathic pulmonary fibrosis (IPF). To date, only supportive care and transplant (for eligible patients) have been available to IPF patients, but these new trial results could lead to FDA approval of the first drugs for IPF.

Mendelsohn Reflects On MD Anderson's #1 U.S. News Ranking

submitted by: mdanderson

President John Mendelsohn, M.D., reflects on the center's ranking as the top hospital for cancer care as determined by U.S. News & World Report's "Best Hospitals" survey.

What's Measured In The U.S. News Ranking

submitted by: mdanderson

Thomas Burke, M.D., executive vice president and physician-in-chief, talks about MD Anderson signature care as recognized by U.S. News & World Report's "Best Hospitals" survey.

A Team Approach for Treating T-Cell Lymphoma

submitted by: mdanderson
Of the approximately 76,000 new patients who will be diagnosed with non-Hodgkin lymphoma (NHL) this year, 15% will have peripheral T-cell lymphoma (PTCL). To meet these challenges, we've assembled a world-class team of medical oncologists, dermatologists, radiation therapists, hematopathologists and stem cell transplant experts to create a multidisciplinary T-cell lymphoma working group. Chaired by Younes, the group discusses challenging cases and recent clinical and pre-clinical data in...

Personalized Approach to Cancer Treatment

submitted by: mdanderson

Raymond DuBois, M.D., Ph.D., provost and executive vice president at MD Anderson Cancer Center, discusses how it's possible to evaluate some cancer patients' tumors and prescribe more effective treatments based on those people's specific genetic makeup.

Ronald DePinho, M.D., on the future of cancer treatment and research

submitted by: mdanderson In this clip, MD Anderson president-designate Ronald DePinho, M.D., gives his thoughts on the future of cancer treatment and research. The University of Texas System Board of Regents today (June 9) named Ronald A. DePinho, M.D., president of the UT MD Anderson Cancer Center in Houston. The Board announced Dr. DePinho, a Harvard professor and cancer institute administrator, as president following a special called meeting of regents. Dr. DePinho had been named the sole...

Renato Lenzi, M.D., Oncologist, Colon Cancer Survivor and SCOPE honoree

submitted by: mdanderson
"Without regular colonoscopies and the great treatment I received at MD Anderson, I would be dead," says Renato Lenzi, M.D., clinical associate professor in GI Medical Oncology. After he was diagnosed with colon cancer in 2002 during a screening, Lenzi endured months of treatment that included surgery, six months of chemotherapy and five weeks of chemotherapy with radiation. This cancer warrior is being recognized by his colleagues as the honoree of the 2011 Sprint for Colorectal Cancer...

New Drugs Target Melanoma

submitted by: mdanderson

Two new drugs provide the first new treatments for melanoma in years. However, they don't help everyone and resistance can develop. Michael Davies, M.D., Ph.D., of MD Anderson's Department of Melanoma, discusses next steps.

Cancer Drug Shortage Is Costing Lives

submitted by: mdanderson
Acute myelogenous leukemia (AML) is a fast-progressing cancer that typically takes a patient's life within two to three months if not treated quickly and properly. Cytarabine is the only known drug to affectively treat AML, having a survival rate of 40% to 50%. Without cytarabine, the survival rate is 0%. The number of drugs, including those used to treat cancer, that are in short supply within the United States has tripled since 2005. Hagop Kantarjian, M.D., chair of the Department of...

Michael A. Kron, M.D., M.S.

submitted by: MCW_BBC

Michael A. Kron, M.D., M.S., a professor of Medicine and the Biotechnology and Bioengineering Center at the Medical College of Wisconsin, describes his research on drug discovery with filariasis and infectious disease.